NMRF Awarded Patent

Research Team Receives Patent on Innovative New Method for Processing Platelets

We recently received notice from the United States Patent and Trademark Office that a patent has been granted for our discovery of a more effective method of producing a therapeutic-grade Platelet Lysate (PL). Human-derived PL is currently recognized as the optimal growth supplement for therapeutic-grade cell cultures, used world-wide in the development of cellular and cell-derived therapies. In addition, PL is an orthobiologic commonly used alone and in conjunction with cell therapies (such as PRP and BMAC). We are very


excited about possible future applications, not just in regenerative medicine, but in cancer research and treatment.


The most common orthobiologic is Platelet Rich Plasma (PRP). PL is similar to PRP in that it is platelet-based, but requires the additional step of breaking the platelets open to extract the therapeutic proteins, which are immediately available to stimulate other cells where they are injected. Whereas PRP works as an “extended release” of therapeutic proteins, PL is “fast acting.” We envision this patent having future clinical applications for patients with neuromuscular and musculoskeletal disorders.  According to Ryan Dregalla, PhD -  “With better methods of creating PL, it will be possible to enhance the benefits of platelet-based therapies by delivering proteins to assist in reprogramming cells in orthopedic injuries that cause chronic inflammation and pain. In addition, PL holds great promise to markedly improve the quality of pharmaceutical-grade cell cultures to resolve diseases that presently have no effective treatment.”


Currently, creation of PL requires that the PRP be frozen and thawed multiple times. However, this method tends to damage many of the proteins in the process. Dr. Dregalla and NMRF’s research associate, Yvette Uribe, discovered a method that enables them to extract proteins from more than 70% of platelets (as opposed to 30% with the freeze-thaw method) without damaging them. Another benefit is that the new method takes only 10 minutes, less than a third of the time it took when using the traditional method. Also, there is no residue or hazardous material left behind.


The patent, “Method of producing the constituents of a therapeutic product derived from mammalian cells,” will allow NMRF to pursue licensing agreements for processing platelets using this method and has potential outside of regenerative medicine. As Dr. Dregalla explains, “the method and technology allow PL to be marketed for use in pharmaceutical-grade cell cultures, which could be an opportunity to generate revenue for the Foundation, and our discovery could be utilized in various new ways in the future.”